Mannkind CORP

MannKind Corporation announced a $50 million private placement financing, primarily to fund a $45 million CVR payment following FDA approval of Furoscix ReadyFlow.

MannKind Corporation announced FDA approval for Afrezza inhalation powder for children and adolescents aged 6 and older with type 1 and type 2 diabetes.

The FDA has released MannKind from a long-standing postmarketing requirement regarding pulmonary malignancy risks for Afrezza.

MannKind Corporation stockholders re-elected nine directors, approved executive compensation, and ratified its auditor.

MannKind Corporation announced first quarter 2026 financial results, with total revenues up 15% year-over-year, driven by commercial product sales and royalties, while advancing key pipeline programs.

MannKind Corporation announced robust fourth quarter and full year 2025 financial results, driven by strong commercial portfolio performance and strategic acquisition of scPharmaceuticals.

MannKind Corporation reports increased total revenues for Q3 and 9M 2025, driven by product sales, collaborations, and royalties, alongside the strategic acquisition of scPharmaceuticals Inc. and an impairment loss on its Thirona investment.

MannKind Corporation achieved net income in the second quarter of 2025, driven by strong royalty revenue from Tyvaso DPI and growth in Afrezza sales, while significantly bolstering its liquidity with a new $500 million credit facility from Blackstone.

MannKind Corporation announces increased revenue for Q1 2025, driven by collaborations, services, and royalties, while managing expenses and maintaining a positive income from operations.

MannKind Corporation achieved a profitable third quarter in 2024, driven by significant revenue increases from product sales, collaborations, and royalties.

MannKind Corporation's Q2 2024 results show a complex picture with strong revenue growth driven by collaborations and royalties, but also increased expenses and a net loss.

MannKind Corporation achieved a profitable first quarter in 2024, driven by increased collaboration revenue and royalties from Tyvaso DPI sales, alongside growth in Afrezza revenue.

MannKind Corporation reported a 22% increase in total revenue for 2025, driven by product sales and collaborations, alongside strategic acquisitions and pipeline advancements.

MannKind Corporation's 2024 10-K filing reveals a return to profitability, driven by increased sales of Tyvaso DPI and Afrezza, alongside strategic pipeline advancements.

MannKind Corporation's 10-K filing details its capital structure, business operations, and strategic focus on developing and commercializing innovative therapeutic products and devices.

Christopher B Prentiss, Chief Financial Officer of Mannkind Corp, reported multiple transactions in common stock on July 15, 2026.

Dominic Marasco, Pres, Endocrine Business Unit of Mannkind Corp, reported a transaction in 3,623 shares of common stock on July 15, 2026.

Stuart A Tross, Chief People & Workpl Officer of Mannkind Corp, reported multiple transactions in common stock on July 15, 2026.

Michael Castagna, Chief Executive Officer and a Director of Mannkind Corp, reported multiple transactions in common stock on July 15, 2026.

Sanjay R Singh, EVP Technical Operations of Mannkind Corp, reported multiple transactions in common stock on July 15, 2026.

David Thomson, EVP Genl Counsel & Secretary of Mannkind Corp, sold 24,109 shares of common stock on July 15, 2026 for $4.05 per share.

MannKind Corporation has issued its proxy statement for the 2026 Annual Meeting of Stockholders, detailing proposals for director elections, executive compensation, and auditor ratification.

MannKind Corporation's proxy statement details proposals for the upcoming annual meeting, including director elections, executive compensation, and auditor ratification.

MannKind Corporation is holding its 2025 Annual Meeting of Stockholders on May 14, 2025, to vote on the election of directors, executive compensation, and the ratification of Deloitte & Touche LLP as the independent auditor.

MannKind Corporation's proxy statement details proposals for the upcoming annual meeting, including the election of directors, executive compensation approval, and ratification of the company's independent auditor.

MannKind Corporation's proxy statement details proposals for the upcoming annual meeting, including director elections, executive compensation, and auditor ratification.

Vanguard Capital Management has reported beneficial ownership of over 15.4 million shares, representing 5% of MannKind Corp's common stock.

State Street Corporation has reported beneficial ownership of 18,683,483 shares, representing 6.1% of MannKind Corp's common stock, as of March 31, 2026.

The Vanguard Group has amended its Schedule 13G filing for MannKind Corp, reporting 0% beneficial ownership following an internal realignment.